[go: up one dir, main page]

SE0301109D0 - Nucleotide vaccine composition - Google Patents

Nucleotide vaccine composition

Info

Publication number
SE0301109D0
SE0301109D0 SE0301109A SE0301109A SE0301109D0 SE 0301109 D0 SE0301109 D0 SE 0301109D0 SE 0301109 A SE0301109 A SE 0301109A SE 0301109 A SE0301109 A SE 0301109A SE 0301109 D0 SE0301109 D0 SE 0301109D0
Authority
SE
Sweden
Prior art keywords
component
dendritic cells
bcr
positive tumor
plasmacytoid dendritic
Prior art date
Application number
SE0301109A
Other languages
English (en)
Inventor
Mallen Huang
Original Assignee
Mallen Huang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallen Huang filed Critical Mallen Huang
Priority to SE0301109A priority Critical patent/SE0301109D0/sv
Publication of SE0301109D0 publication Critical patent/SE0301109D0/sv
Priority to CA002522456A priority patent/CA2522456A1/en
Priority to US10/551,804 priority patent/US10799553B2/en
Priority to CN2004800164612A priority patent/CN1805758B/zh
Priority to PCT/SE2004/000589 priority patent/WO2004089413A1/en
Priority to AU2004227821A priority patent/AU2004227821A1/en
Priority to AT04727465T priority patent/ATE514433T1/de
Priority to EP04727465A priority patent/EP1658097B1/en
Priority to JP2006508023A priority patent/JP2006523688A/ja
Priority to US16/985,393 priority patent/US11298398B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0301109A 2003-04-14 2003-04-14 Nucleotide vaccine composition SE0301109D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE0301109A SE0301109D0 (sv) 2003-04-14 2003-04-14 Nucleotide vaccine composition
CA002522456A CA2522456A1 (en) 2003-04-14 2004-04-14 Nucleotide and cellular vaccine composition
US10/551,804 US10799553B2 (en) 2003-04-14 2004-04-14 Composition comprising a nucleotide sequence encoding an ELA2 fusion protein and plasmacytoid dendritic cells
CN2004800164612A CN1805758B (zh) 2003-04-14 2004-04-14 核酸和细胞疫苗的组分
PCT/SE2004/000589 WO2004089413A1 (en) 2003-04-14 2004-04-14 Nucleotide and cellular vaccine composition
AU2004227821A AU2004227821A1 (en) 2003-04-14 2004-04-14 Nucleotide vaccine composition
AT04727465T ATE514433T1 (de) 2003-04-14 2004-04-14 Nucleotid und zelluläre vakzine-zusammensetzung
EP04727465A EP1658097B1 (en) 2003-04-14 2004-04-14 Nucleotide and cellular vaccine composition
JP2006508023A JP2006523688A (ja) 2003-04-14 2004-04-14 ヌクレオチド・ワクチン組成、ヌクレオチド及び細胞ワクチン組成の産出方法、ワクチン組成、ワクチン組成使用、免疫反応産出方法、疾患の治療または予防方法、抗原提示細胞から成るキット
US16/985,393 US11298398B2 (en) 2003-04-14 2020-08-05 Method of treating a philadelphia chromosome-positive tumor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301109A SE0301109D0 (sv) 2003-04-14 2003-04-14 Nucleotide vaccine composition

Publications (1)

Publication Number Publication Date
SE0301109D0 true SE0301109D0 (sv) 2003-04-14

Family

ID=20291035

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301109A SE0301109D0 (sv) 2003-04-14 2003-04-14 Nucleotide vaccine composition

Country Status (9)

Country Link
US (2) US10799553B2 (sv)
EP (1) EP1658097B1 (sv)
JP (1) JP2006523688A (sv)
CN (1) CN1805758B (sv)
AT (1) ATE514433T1 (sv)
AU (1) AU2004227821A1 (sv)
CA (1) CA2522456A1 (sv)
SE (1) SE0301109D0 (sv)
WO (1) WO2004089413A1 (sv)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301109D0 (sv) * 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
JPWO2008065752A1 (ja) * 2006-11-30 2010-03-04 国立大学法人北海道大学 ｄｉＲＮＡを有効成分とする免疫治療用薬剤
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
BRPI0812914B1 (pt) * 2007-06-19 2017-09-12 Coloplast A/S Body waste collection device
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
US9012399B2 (en) 2008-05-30 2015-04-21 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
US20100330117A1 (en) * 2008-09-26 2010-12-30 Salubrious Pharmaceutical, Llc Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis, non-viral based cancers, alzheimers's disease, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis, west nile virus, fibromyalgia, shingles, gout, migraine headaches, senile dementia, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c
MX2011003277A (es) * 2008-10-14 2012-09-21 Salubrious Pharmaceuticals LLC Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral.
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
WO2011014871A1 (en) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
EP2542230A4 (en) 2010-03-05 2013-08-28 Harvard College PROMOTING THE ADHESION OF SKELETAL MUSCLE STEM CELLS BY SIMULTANEOUS ADMINISTRATION OF VEGF AND IGF-1
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
CN107648668B (zh) 2010-10-06 2021-06-18 哈佛学院董事会 用于基于材料的细胞疗法的可注射的成孔水凝胶
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
WO2012148684A1 (en) 2011-04-27 2012-11-01 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
WO2012149358A1 (en) 2011-04-28 2012-11-01 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
AU2012261848B2 (en) 2011-06-03 2017-06-15 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
CA2861107A1 (en) * 2012-01-13 2013-07-18 President And Fellows Of Harvard College Controlled delivery of tlr agonists in structural polymeric devices
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
EP2897639A4 (en) 2012-09-21 2016-05-04 Frank Bedu-Addo IMPROVED VACCINATE COMPOSITIONS AND METHODS OF USE
JP6444321B2 (ja) * 2013-02-22 2018-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化主要組織適合性遺伝子複合体を発現するマウス
WO2014164640A1 (en) * 2013-03-11 2014-10-09 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
EP3411475B1 (en) 2016-02-06 2025-08-27 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
CN115537372A (zh) 2016-07-13 2022-12-30 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
EP3493842A4 (en) 2016-08-02 2020-07-29 President and Fellows of Harvard College BIOMATERIALS TO MODULATE IMMUNE RESPONSES
WO2018071959A1 (en) * 2016-10-21 2018-04-26 Biosceptre (Uk) Limited Cytotoxic particles
CN107375950B (zh) * 2017-08-02 2020-10-09 深圳大学 一种重组Gal-1过敏环境免疫耐受诱导模型及建立方法
CN112912389B (zh) * 2018-06-19 2024-04-19 H·李·莫菲特癌症中心和研究所公司 使用i型干扰素和cd40配体的溶瘤病毒或抗原呈递细胞介导的癌症治疗
BR112021000620A2 (pt) 2018-07-15 2021-04-20 Enochian BioPharma, Inc. métodos e composições com uso de células dendríticas recombinantes para terapia contra câncer
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
CN112048007B (zh) * 2020-09-11 2022-07-12 北京美康基免生物科技有限公司 一种通用型新型冠状病毒疫苗及其制备方法
GB202014920D0 (en) * 2020-09-22 2020-11-04 Unikum Therapeutics Aps Methods for treating cancer and autoimmune and inflammatory diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000255A1 (en) 1994-06-23 1996-01-04 Raymond Enterprises, Inc. Making lenticular optical systems and apparatus therefor
EP0772619B2 (en) * 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
DE69838294T2 (de) * 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
AU6144499A (en) * 1998-09-15 2000-04-03 University Of Pittsburgh In situ injection of antigen-presenting cells with genetically enhanced cytokineexpression
DE69918146T2 (de) * 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
US6338040B1 (en) * 1999-02-12 2002-01-08 Agren, Inc. Method for delaying the development in pest species of resistance to control techniques, using insurance to encourage correct uses of refuges
CA2367692A1 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
CA2309313A1 (en) 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
US6780405B1 (en) 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
US7385023B1 (en) * 2000-11-15 2008-06-10 Trustees Of Boston University Cancer immunotherapy and diagnosis using cytochrome P450 1B1
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
AU2002252179A1 (en) * 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
JP4504023B2 (ja) 2002-03-22 2010-07-14 ザイモジェネティクス インコーポレーティッド 抗ｉｌ−ｔｉｆ抗体および炎症において使用する方法
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP2557164A1 (en) * 2003-02-18 2013-02-13 Kevin M. Slawin Induced activation in dendritic cells
SE0301109D0 (sv) * 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
GB2402675B (en) * 2003-05-12 2008-02-20 Oxitec Ltd Resistance dilution

Also Published As

Publication number Publication date
WO2004089413A1 (en) 2004-10-21
CA2522456A1 (en) 2004-10-21
US11298398B2 (en) 2022-04-12
AU2004227821A1 (en) 2004-10-21
US20210077565A1 (en) 2021-03-18
US20070071722A1 (en) 2007-03-29
JP2006523688A (ja) 2006-10-19
EP1658097A1 (en) 2006-05-24
US10799553B2 (en) 2020-10-13
EP1658097B1 (en) 2011-06-29
ATE514433T1 (de) 2011-07-15
CN1805758A (zh) 2006-07-19
CN1805758B (zh) 2012-04-25

Similar Documents

Publication Publication Date Title
SE0301109D0 (sv) Nucleotide vaccine composition
DE60324430D1 (de) Methode um rekombinante proteine in cho zellen zu exprimieren
ATE500323T1 (de) Subtilisin-variante
WO2002016583A3 (en) Constructs and their use in metabolic pathway engineering
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
PE20090731A1 (es) Metodos de produccion de proteinas basados en medios de cultivos celulares que comprenden compuestos anti-senescencia
LU91680I2 (fr) "rilonacept et ses dérivés pharmaceutiquement acceptables (ARCALYSR)"
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
DK1409506T3 (da) Fremgangsmåder og sammensætninger til RNAi-formidlet inhibering af genekspression i pattedyr
PT1240325E (pt) Polipéptidos homólogos de il-17 e il-17r e suas utilizações terapêuticas
IS6750A (is) Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
BR0108959A (pt) Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
EA201100071A1 (ru) Новые композиции и способы
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
WO2006130525A3 (en) Methods for immunotherapy of cancer
ATE304603T1 (de) Induzierendes alphavirengen- expressionssystem
DE69834565D1 (de) Schnell erzeugung von stabilen säugertier-zellinien mit gewinnung eines hohen gehalts von recombinanten proteine
ATE418344T1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
WO2006096989A3 (en) Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the gly-gly-ala domain for enhanced transient gene expression
MX2007008980A (es) Acidos nucleicos para apoptosis de celulas cancerigenas.